Fixed ratio combination of basal insulin and GLP-1 receptor agonist
IGlarLixi 2:1 pen subcutaneous once daily titrated
IGLARLIXI2_SC_TIT_QD
Used throughout the trial. Combined with the other iGlarLixi nodes only in a prespecified sensitivity analysis.
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.05 (-1.38 to -0.72) | 0.60 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.10 (-1.55 to -0.64) | 0.70 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin glargine | MD -0.50 (-1.48 to 0.55) | 0.87 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 0.10 (-0.60 to 0.70) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.12 (-1.21 to 0.91) | 0.47 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.48 (-0.61 to 1.53) | 0.10 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.82 (-0.85 to 2.46) | 0.30 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin glargine | MD -1.09 (-5.91 to 3.95) | 0.41 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 2.08 (-0.60 to 5.16) | 0.63 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -4.15 (-9.12 to 1.21) | 0.63 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 7.55 (2.07 to 18.67) | 0.57 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 9.95 (2.94 to 22.15) | 0.83 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin glargine | OR 2.46 (0.76 to 7.14) | 0.89 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.34 (0.05 to 1.78) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.49 (1.67 to 7.13) | 0.34 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.29 (0.46 to 3.80) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.96 (1.07 to 7.29) | 0.20 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.83 (0.61 to 1.12) | 0.60 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.86 (0.47 to 1.57) | 0.71 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.28 (1.63 to 3.19) | 0.57 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.23 (1.34 to 3.70) | 0.57 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.00 (0.70 to 1.43) | 0.71 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.80 (0.27 to 2.29) | 0.71 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.70 (0.03 to 23.59) | 0.63 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.64 (0.04 to 10.13) | 0.53 |
Trials
- S002992887 randomized · 26 weeks
- IDEALINSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi2021 · 91 randomized · 24 weeks
- Lixilan-O-APA Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)2019 · 878 randomized · 24 weeks
- Lixilan-L-CNA Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled on Basal Insulin With or Without Oral Antidiabetic Drug(s)2019 · 426 randomized · 30 weeks
- LIXILAN JP-O1A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period2016 · 321 randomized · 52 weeks
- LIXILAN JP-LA Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs2016 · 513 randomized · 26 weeks
- LIXILAN JP-O2A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)2016 · 521 randomized · 26 weeks
- LixiLan-LA Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 736 randomized · 30 weeks
- LixiLan-OA Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 1,170 randomized · 30 weeks
- NCT01476475A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients2011 · 323 randomized · 24 weeks